Anger as NICE limits access to Alzheimer's drugs

Doctors, patients and carers of people with Alzheimer's disease have reacted in anger to this week's decision by NICE to reject their concerns and limit access to drugs to the moderate stages of the disease.

NICE will recommend to the NHS next month that donepezil, galantamine and rivastigmine should be considered as options in the treatment of people with moderate Alzheimer’s disease.  

Five separate appeals were lodged in an unprecedented protest involving 9,000 people against initial guidance that the drugs in question were not cost effective for the NHS in England and Wales.  

Neil Hunt, chief executive of the Alzheimer’s Society, asked: ‘What sort of society have we become when the health of hundreds of thousands are sold to save just £2.50 a day?’  

NICE guidance bans GPs from prescribing memantine, the only licensed drug to treat late-stage symptoms. Memantine is recommended as part of clinical studies for people with moderately-severe to severe Alzheimer’s.  
 

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

Fitness to practise and revalidation to continue despite pandemic, GMC confirms

Fitness to practise and revalidation to continue despite pandemic, GMC confirms

Revalidation and ongoing fitness to practise cases will continue despite huge pressure...

UK COVID-19 vaccination programme tracker

UK COVID-19 vaccination programme tracker

GPs across the UK are playing a leading role in the largest-ever NHS vaccination...

Supporting men and children experiencing domestic violence through general practice

Supporting men and children experiencing domestic violence through general practice

IRIS is an evidence-based programme designed to reach female survivors of domestic...

Learn about neurological aspects of 'long COVID' at a MIMS Learning webinar

Learn about neurological aspects of 'long COVID' at a MIMS Learning webinar

Loss of taste and smell and neurological aspects of 'long COVID' infection will be...

COVID-19 vaccine stocks must not be diverted to large sites ahead of local GPs, warns BMA

COVID-19 vaccine stocks must not be diverted to large sites ahead of local GPs, warns BMA

The government must ‘ramp up’ COVID vaccine supplies to general practice and avoid...

GP-led sites behind almost three quarters of COVID-19 jabs in England

GP-led sites behind almost three quarters of COVID-19 jabs in England

GP-led vaccination sites have delivered nearly three quarters of COVID-19 vaccine...